http://www.summitplc.com/
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the superbug C. difficile

Summit entering exciting stage of its development
By John Harrington August 22 2013, 7:49am 'We now look forward to advancing clinical trials into patient populations for both the DMD and CDI programmes to further evaluate these potential life-changing treatments for two serious diseases,' said Glyn Edwards, chief executive officer of Summit."We now look forward to advancing clinical trials into patient populations for both the DMD and CDI programmes to further evaluate these potential life-changing treatments for two serious diseases," said Glyn Edwards, chief executive officer of Summit.

Summit (LON:SUMM), the high-flying drug discovery company, said the first half of its financial year had been an excellent period for the company.

On the product development front, the company’s phase 1b patient clinical trial of SMT C1100, its Duchenne Muscular Dystrophy (DMD) drug, is on track to start before the end of this year, while its novel antibiotic SMT 19969, for the treatment of C. difficile infection, saw positive results from its Phase 1 clinical trial in healthy volunteers, showing it to be safe and well-tolerated.

As is to be expected from a drug discovery and development company that is currently relying chiefly on grant and other not-for-profit funding for its revenue, the company made a loss in the six months to the end of July, but at £2.38mln this was virtually unchanged from the year before, despite spending on research & development rising to £2.08mln from £1.85mln.

Cash at the end of July stood at £6.0mln, up from £4.8mln a year earlier. The company said operational expenditure during the reporting period was in line with expectations.

“The company is entering an exciting stage in its development as our two programmes prepare to commence patient clinical trials. The promise these programmes are showing as life-changing treatments for two serious diseases is being endorsed externally by respected organisations that include the Biomedical Catalyst and the Wellcome Trust,” noted Glyn Edwards, chief executive officer of Summit.

Shares in Summit have doubled over the last month

Summit Corporation: N+1 Singer shifts target price from 8.80p to 10.70p keeping its buy recommendation

Looking good... I'm staying in for the long term..having got in @ 3.5p some while ago it's temting to take the profit but ....

2007 they were 120p.

Summit Granted Key Composition of Matter Patent...

HUG


Summit Corporation plc
('Summit' or 'the Company')

SUMMIT GRANTED KEY COMPOSITION OF MATTER PATENT FOR UTROPHIN MODULATOR SMT C1100 IN THE TREATMENT OF DMD

Oxford, UK, 28 August 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, announces that the United States Patent and Trademark Office has issued a composition of matter patent that protects SMT C1100 and its use in the treatment of the fatal muscle wasting disease DMD.

United States Patent number 8,518,980 is entitled "Treatment of Duchenne Muscular Dystrophy" and will provide a period of exclusivity for the small molecule utrophin modulator SMT C1100 through at least November 2028.

"The grant of this cornerstone patent for SMT C1100 in a key commercial market represents a critical component in our strategy for advancing this promising utrophin modulator in the treatment of DMD," commented Glyn Edwards, Chief Executive Officer of Summit. "Together with the recently issued US patent covering the use of SMT C1100 in combination with steroids, the intellectual property estate protecting this potential life-changing drug has been significantly strengthened as we prepare to start patient clinical trials during the second half of this year."

The patent "Drug Combinations for the Treatment of Duchenne Muscular Dystrophy" was recently issued by the US Patent and Trademark Officer and covers the use of SMT C1100 in combination with steroids such as prednisolone and deflazacort (US Patent number 8,501,713).

About DMD and SMT C1100
DMD is a progressive muscle wasting disease that affects around 1,500 boys and young men in the UK. It is caused by different genetic faults in the gene that encodes dystrophin, a protein that is essential for the healthy function of muscles. There is no cure and life expectancy is around the mid-twenties. Utrophin protein is the functional equivalent of dystrophin and non-clinical studies have shown it can substitute for dystrophin to maintain the healthy function of skeletal and cardiac muscle. Utrophin modulation has the potential to slow down or even stop the progression of DMD regardless of the dystrophin mutation. Importantly it is also expected to be complementary to other DMD therapeutic approaches in development. SMT C1100, an orally administered small molecule, is Summit's most advanced utrophin modulator and it is expected to start clinical trials in DMD patients during the second half of 2013.

- END -

More good patent news released this morning...who knows, in a couple of years time it could be worth 120p again !

Excellent news, some positive territory today!

Summit to Present New Data on C difficile Antib...

HUG


Summit Corporation plc
('Summit' or 'the Company')

SUMMIT TO PRESENT NEW DATA ON C. DIFFICILE ANTIBIOTIC PROGRAMME AT ICAAC 2013

Oxford, UK, 4 September 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection ('CDI'), announces that clinical and preclinical data on its novel, selective antibiotic SMT19969 for the treatment of CDI will be reported in podium and poster presentations at the 53rd annual Interscience Conference on Antimicrobial Agents and Chemotherapy ('ICAAC') meeting in Denver, Colorado, USA from 10-13 September 2013.

Summit has been selected by an expert panel of the American Society for Microbiology to give an oral presentation summarising SMT19969 in the 'Early New Antimicrobial Agents Poster Summary Session', which will highlight the next wave of compounds with potential to move through the clinical development process. This presentation will feature Phase 1 clinical trial and preclinical data which will be included in five posters being reported by Summit and its key collaborators during the conference.

Glyn Edwards, Chief Executive Officer of Summit commented: "Summit is pleased to have been selected to showcase the data on our novel and selective antibiotic SMT19969 for the treatment of C. difficile infection at this major international conference."

Further details about the presentations are below and the full abstracts are available online at www.icaac.org/index.php/online-program-planner.

Tuesday 10 September 2013

Oral Presentation: Early New Antimicrobial Agents Poster Summary Session (2.30-4.30pm MDT)

SMT19969: A Selective Therapy for C. difficile Infection (R Vickers)

Poster Session 018: Clostridium difficile (12.00-2.00pm MDT)

K-167 Effects of a Novel Antimicrobial (SMT19969) for Treatment of Clostridium difficile Infection (CDI) on Gut Flora; EL Best, R Vickers, M Wilcox.

Wednesday 11 September 2013

Poster Session 082: Agents Acting Against Clostridium difficile (11:00am-1:00pm MDT)

F-624 Comparative in vitro Activity of SMT19969, a New Antimicrobial Agent, Against Clostridium difficile and 203 Gram-positive Aerobic and Anaerobic Gut Flora Isolates; EJ Goldstein, DM Citron.

F-625 SMT19969: Effects of Varying MIC Parameters on the in vitro activity against Clostridium difficile; A Wise, D Corbett, P Thommes, S Birchall, R Vickers, PA Warn.

F-626 SMT19969 for Clostridium difficile Infection (CDI): Phase 1 Study Investigating Safety and Pharmacokinetics in Healthy Male Subjects; R Vickers, N Robinson, E Best, M Wilcox, G Tillotson, R Echols.

F-631b Comparative in vitro activity of SMT19969, a new antimicrobial agent against 169 less common intestinal clostridium species: Implications for recurrence; EJC Goldstein, DM Citron.

Copies of these presentations will be available on the Summit website during the ICAAC meeting.

- END -

Trying 10p again.

Yep, looking good ...but expecting profit taking this afternoon.. however, I'm staying in for a long while yet!

Topped up on LBB ... looking interesting ahead of results due soon.

Looks good, although tends to + or - 10%. Good to hold more for the future.

Still looking skywards.

N+1 Singer needs to update this share. They are slow sometimes. :-))

Buying at 12p :-))

A 2 bagger for me and still looking up.

SUMMIT PRESENTS NEW PRECLINICAL AND CLINICAL DATA ON SELECTIVE C. DIFFICILE ANTIBIOTIC SMT19969 AT ICAAC 2013

:-))

Summit presentations points to antibiotic's potential
By Ian Lyall September 11 2013, 7:33am The results from studies of SMT19969 are being presented at a prestigious industry event in Colorado.The results from studies of SMT19969 are being presented at a prestigious industry event in Colorado.

Drug developer Summit (LON:SUMM) is presenting data that points to the huge potential of its antibiotic in tackling the C.difficile superbug.

The results from studies of SMT19969 are being presented at a prestigious industry event in Colorado.

Delegates will be told that the company’s phase-one clinical trial of 56 healthy volunteers revealed the drug to be well tolerated in all doses and sparing on gut flora.

The major bacteria groups were largely unchanged with the exception of total Clostridia, which were reduced during treatment.

Results from preclinical efficacy studies were similarly encouraging.

Evaluating the potency and selectivity of SMT19969, they reveal it is highly targeted, but kills all strains of C.diff tested.

A separate analysis of SMT19969 reveals its use with traditional antibiotics does not diminish its potency.

The data will be revealed in five posters and podium presentation at the 53rd annual Interscience Conference on Antimicrobial Agents and Chemotherapy (IAAC) meeting in Denver.

Summit chief executive Glyn Edwards said: "These new data presented at ICAAC 2013 further validates the promise of SMT19969 as a novel and highly targeted antibiotic for the treatment of this serious infectious disease.

"These results demonstrate that SMT19969 selectively kills all C.difficile strains tested, is highly sparing of healthy gut flora and shows no reduction in activity when used in combination with other antibiotics. This profile is encouraging for treating CDI and significantly reducing rates of recurrent disease and we look forward to advancing SMT19969 into phase-two clinical trials in the second half of 2014."

Come on N+1 Singer upgrades needed fast.

Come on N+1 Singer upgrades needed fast.